Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects

Meropenem-vaborbactam is a fixed combination of the novel β-lactamase inhibitor vaborbactam and the carbapenem antibiotic meropenem, developed for the treatment of serious infections caused by drug-resistant Gram-negative bacteria. The safety, tolerability, and pharmacokinetics (PK) of vaborbactam a...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Antimicrob Agents Chemother
Prif Awduron: Rubino, Christopher M., Bhavnani, Sujata M., Loutit, Jeffery S., Morgan, Elizabeth E., White, Dan, Dudley, Michael N., Griffith, David C.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Microbiology 2018
Pynciau:
Clinical Therapeutics
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5914003/
https://ncbi.nlm.nih.gov/pubmed/29437614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02228-17
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg